Talis Biomedical

Talis Biomedical Tangible Book Value per Share

Delisted

The Tangible Book Value per Share of Talis Biomedical (TLIS) as of Nov 2, 2026 is 37.98 USD. In the previous year, Tangible Book Value per Share was 69.64 USD — a change of -45.47% (lower).

Tangible Book Value per Share

37.98USD

YoY

-45.47%

Last updated:

Tangible Book Value per Share of Talis Biomedical is 2023 37.98 USD. Tangible Book Value per Share of Talis Biomedical was 2022 69.64 USD. It decreases by -45.47% lower compared to the previous year.

The Talis Biomedical Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
4.23 USD
Jan 1, 2019
11.88 USD
Jan 1, 2020
100.21 USD
Jan 1, 2021
128.56 USD
Jan 1, 2022
69.64 USD
Jan 1, 2023
37.98 USD
The Talis Biomedical Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
37.98USD-45.47%
69.64USD-45.83%
128.56USD+28.30%
100.21USD+743.74%
11.88USD+180.93%
4.23USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Talis Biomedical Stock analysis

What does Talis Biomedical do? Talis Biomedical Corp develops and commercializes the Talis One system, a cloud-enabled molecular diagnostic platform comprising a compact instrument, single-use test cartridges, and software linked to a central cloud database. The company targets healthcare providers seeking point-of-care molecular testing for infectious diseases, respiratory infections, women's health conditions, and sexually transmitted infections (STIs). Its products include assay kits for respiratory panels combining influenza A, influenza B, and COVID-19 tests, designed for use by untrained personnel. Revenue is generated through sales of the Talis One system and associated assay kits to healthcare facilities requiring rapid, accurate diagnostic solutions. The Talis One system is positioned for central laboratory-level accuracy at the point of care, appealing to clinics and hospitals needing efficient diagnostic tools. The Respiratory Panel, integrating influenza A, influenza B, and COVID-19 assays, addresses high-demand areas in infectious disease testing. The company's focus on women's health and STI-related assays expands its market reach within specialized healthcare segments. Sales of these products are directed toward healthcare providers who prioritize accessible, user-friendly diagnostic technology without requiring extensive training. Talis Biomedical Corp's commercial strategy centers on delivering diagnostic solutions that combine advanced molecular testing with ease of use. The Talis One system and its assay kits are marketed to healthcare facilities aiming to enhance diagnostic capabilities at the point of care. By targeting respiratory infections, women's health, and STIs, the company addresses key areas where rapid, accurate testing is critical. Revenue streams are derived from the sale of both the hardware platform and the consumable test kits, ensuring ongoing customer engagement through recurring purchases. Talis Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Talis Biomedical stock

Tangible Book Value per Share of Talis Biomedical is 37.98 USD in 2023.

Tangible Book Value per Share of Talis Biomedical changed from 69.64 USD to 37.98 USD, representing a -45.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Talis Biomedical since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Talis Biomedical

All Key Metrics — Talis Biomedical